Therapeutic potential of JAK2 inhibitors.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn , Issue , 2009, Pages 636-642

  Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAZOLE DERIVATIVE; INCB018424; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; LESTAURTINIB; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; SULFONAMIDE; TG101348;

ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; MISSENSE MUTATION; MOUSE; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; REVIEW; SIGNAL TRANSDUCTION; SPLENOMEGALY; WEIGHT GAIN;

ANIMALS; CARBAZOLES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; JANUS KINASE 2; MICE; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRROLIDINES; SIGNAL TRANSDUCTION; SPLENOMEGALY; SULFONAMIDES; WEIGHT GAIN;

EID: 77949468470     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2009.1.636     Document Type: Review

References (41)